56 results about "Protamine" patented technology

The invention discloses tetrapeptide KA4 with an anti-fatigue function as well as a preparation method and application of the tetrapeptide KA4, and belongs to the technical field of biology. The tetrapeptide KA4 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is KYPA, and the tetrapeptide KA4 has strong binding capacity with KEAP1, AMPK and LDH, can significantly reduce the serum lactic acid content of a fatigue model mouse and significantly increase the load swimming time of the fatigue model mouse, has an anti-fatigue function, and can be applied to development of functional food for relieving fatigue.

The invention provides 6-site polysubstituted aminoethoxy phenyl pyridinium salt-gamma-cyclodextrin with a structure as shown in a formula (I). The preparation method of the 6-site poly-substituted aminoethoxy phenyl pyridinium salt-gamma-cyclodextrin is simple and convenient, and the prepared 6-site poly-substituted aminoethoxy phenyl pyridinium salt-gamma-cyclodextrin has good biocompatibility, and can be used for preparing the 6-site poly-substituted aminoethoxy phenyl pyridinium salt-gamma-cyclodextrin. In in-vitro pig plasma experiments and in-vivo mouse experiments, the 6-site polysubstituted aminoethoxy phenyl pyridinium-gamma-cyclodextrin can well neutralize heparin and shows neutralizing activity better than that of protamine, and the cyclodextrin derivative has wide application prospects in the fields of biology and medicine.

The invention discloses a nanofiber membrane for inflammatory factor adsorption and a preparation method thereof, and belongs to the technical field of biomedical materials, the nanofiber membrane structurally comprises a positively charged nanofiber membrane and a negatively charged nanofiber membrane which are arranged in sequence; the positively charged nanofiber membrane is obtained by blending and electrospinning a main polymer, a positively charged ligand and a cross-linking agent which are used as raw materials and then performing in-situ cross-linking; the positively charged ligand is at least one of polylysine, polyethyleneimine, polyarginine or protamine; the electronegative charge nanofiber membrane is obtained by in-situ cross-linking after blending and electrospinning of a main polymer, an electronegative charge ligand and a cross-linking agent which are used as raw materials; the negatively charged ligand is at least one of heparin, chondroitin sulfate or heparan sulfate. The nanofiber membrane is simple in preparation process, the surface of the membrane has abundant charge binding sites, the charge density is large, the mechanical strength is high, and the adsorption effect on inflammatory factors is good.

The invention discloses low-endotoxin macromolecule PDRN, a preparation method and application. A freeze-dried white powder sample is obtained through fish testis pretreatment, fish sperm cell enzymolysis, deproteinization, ultrasonic pretreatment, nuclease enzymolysis, primary alcohol precipitation, redissolution and filtration, endotoxin control, secondary alcohol precipitation, alcohol washing and freeze-drying. Fragmentation is carried out by combining ultrasonic waves with nuclease enzymolysis, the use amount of enzyme can be effectively reduced, the molecular weight of the product can be accurately controlled, operation is easy, and the industrialization cost is low. The method comprises the following steps: carrying out enzymolysis on protamine cells through protease K, releasing protamine DNA, carrying out fragmentation on a PDRN sample by using ultrasonic waves and nuclease, and carrying out deep filtration and triton 114 washing to obtain the protamine with the molecular weight controllable interval of 500bp-4000bp; the content of endotoxin is less than or equal to 0.5 EU / mg, and the content of protein is less than or equal to 1.0%. The finished product is obtained by freeze-drying the PDRN wet solid, and the quality and the additional value of the product are improved.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention relates to a preparation method of a CpG ODN nano immune complex, which comprises the following steps: (1) uniformly mixing a protamine solution with a certain concentration and a CpG motif-containing oligodeoxynucleotide CpG ODN aqueous solution with a certain concentration according to a certain ratio, and carrying out electrostatic compounding assembly at room temperature to form a suspension; and (2) applying energy to the suspension to disperse / homogenize uniformly to form the suspension of the nano-composite. The nano-composite prepared by the method disclosed by the invention is controllable in particle size and controllable in surface charge. The nano particles formed under the preparation condition of an optimized proportion are uniformly dispersed, good in stability, good in resolubility after freezing, and good in long-term storage stability. The preparation method provided by the invention is simple, does not involve toxic and harmful chemical substances, and is suitable for amplification. Compared with the prior art, the preparation method provided by the invention can obviously improve the effective concentration of the effective active substance CpG ODN in the nano immune complex. The invention also relates to the nano immune complex prepared by the method and application thereof. Cell and animal experiments prove that the nano immune complex prepared by the method has good immunostimulatory activity, can stimulate the maturation of related immune cells and induce the secretion of related cytokines, can be independently used as an immunomodulator, and can also be used as an immunologic adjuvant to be combined with various antigens to be used as a vaccine preparation as a whole. The nano immune complex has good application prospects in the fields of inducing and activating immune cells to mature, releasing cytokines, resisting allergic diseases, preventing and treating microbial infectious diseases, vaccine adjuvants, resisting tumor immunotherapy and resisting Alzheimer's disease.

The invention discloses an efficient extraction method of blue fox sperm DNA, and belongs to the technical field of molecular biology. Aiming at the structural characteristics that chromatin of the blue fox sperms is highly condensed, histone is replaced by protamine, and a stable nucleoprotein complex is formed through an intermolecular disulfide bond, the invention provides an efficient DNA extraction method suitable for the blue fox sperms. According to the method, based on the synergistic effect of three chemical reagents, namely SDS, PK and DTT, full lysis of the sperm cells of the blue foxes is achieved, and then efficient enrichment of sperm DNA of the blue foxes can be achieved by combining a conventional DNA extraction method. According to the efficient extraction method of the blue fox sperm DNA provided by the invention, the yield and integrity of the blue fox sperm DNA are remarkably improved, and the limitation that sperm chromatin is difficult to effectively lyse by a conventional method is overcome; the method provides reliable technical support for research on genetic diversity evaluation, population management, molecular breeding and the like of the blue foxes, and has the potential of popularization and application in other high-condensation sperm species.

A nanoparticle drug based on a small interfering RNA (siRNA) targeting JFK and use thereof are provided. Nucleotide sequences of the sense strand and the antisense strand of the siRNA targeting JFK are set forth in SEQ ID NO: 1 and SEQ ID NO: 2, respectively. Liposomes can be used to encapsulate the complex of the siRNA and a protamine to produce a nanoparticle drug targeting JFK, which may be used to treat a disease related to abnormally-high expression of JFK. In this disclosure, breast cancer 4T1 cell-based tumor-bearing mice serve as the model for evaluating the anti-tumor activity of combined therapy involving the nanoparticle drug targeting JFK and radiotherapy. The results reveal that this combined therapy exhibits superior anti-tumor activity compared to the control group.

The invention discloses a coregonus peled protamine peptide enzymolysis device and method, and belongs to the technical field of coregonus peled protamine peptide enzymolysis, and the coregonus peled protamine peptide enzymolysis method comprises the steps of pretreatment, ultrasonic-assisted acid extraction, precipitation and composite purification, and multistage impurity removal and refining. The target protein is promoted to be fully dissolved out; the coregonus peled protamine peptide enzymolysis device is composed of a supporting mechanism, a stirring mechanism, a first adjusting mechanism, a second adjusting mechanism and a switching mechanism. The supporting mechanism is matched with various stirring barrels through external threaded pipes of different specifications. The first adjusting mechanism adjusts the immersion position of the stirring blade by means of bevel gear transmission, and the deep vortex and cavitation effect are avoided; the second adjusting mechanism drives a screw rod through a gear to adjust the distance between the stirring blades and the barrel wall, and a stirring dead zone is eliminated; the switching mechanism completes vacuum degassing and nitrogen filling through a three-way switching valve, foam is inhibited, and sample oxidation is prevented.

The invention discloses a hexapeptide VA6 with an anti-fatigue function as well as a preparation method and application thereof, and belongs to the technical field of biology. The hexapeptide VA6 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is VGVVVA, the binding capacity with AMPK and LDH is high, the liver glycogen content of a fatigue model mouse can be remarkably increased, the serum urea nitrogen content of the fatigue model mouse can be remarkably reduced, the fatigue phenotype of the fatigue model mouse can be remarkably relieved, and the load swimming time of the fatigue model mouse can be remarkably prolonged; the food has an anti-fatigue function and can be applied to development of functional food for relieving fatigue.

The present invention belongs to the field of molecular biology and genetics, and in particular relates to a method for editing a bovine gene based on Pro-iCHI. The present invention provides a method for editing a bovine gene based on Pro-iCHI. Protamine is transiently expressed in gene-edited b-haSCs, which are then injected to mature oocytes to obtain reconstructed embryos. Protamine can eliminate abnormal DNA methylation resulting from oocyte intracytoplasmic haSCs injection and enable the nucli to compress into sperm-like structures, and the obtained bovine Pro-iCHI embryos can successfully develop into blastocysts, with a blastocyst rate comparable to that of the embryos obtained by in vitro fertilization. Moreover, in the present invention, a protamine-encoding gene is inserted into a Saccharomyces cerevisiae protein expression vector for transient expression, which ensures that abnormal DNA methylation is erased, without integration into the genome resulting in the insertion of exogenous genes.

The invention discloses a pentapeptide YP5 with a function of relieving diabetic kidney injury as well as a preparation method and application of the pentapeptide YP5, and belongs to the technical field of biology. The pentapeptide YP5 is screened from pacific salmon protamine enzymatic hydrolysate, the amino acid sequence is YVAAP, and the pentapeptide YP5 has the function of relieving the diabetic kidney injury, can remarkably reduce the content of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing the medicine for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.

The invention belongs to the technical field of biological medicine, and particularly relates to a heparin small molecule antagonist-quaternary ammonium salt macrocyclic compound and a preparation method thereof. The quaternary ammonium salt macrocyclic compound disclosed by the invention comprises three piperazine functionalized quaternary ammonium salt macrorings and four methylated quaternary ammonium salt macrorings; the quaternary ammonium salt macrocyclic compound can be used for preparing a heparin small molecule antagonist. The compound shows excellent antagonism efficiency on ungraded heparin and low-molecular-weight heparin, and shows a wide therapeutic dose window; and the antagonism efficiency and dosage window of the protamine are superior to those of clinically used protamine. Besides, in-vivo and in-vitro safety evaluation proves that the quaternary ammonium salt macrocycle has good biocompatibility, and shows clinical transformation potential as a protamine substitute as a small molecule antagonist.

The present invention relates to an anticoagulant heparin-derived oligosaccharide biphenyl dimer, and a preparation method therefor and a use thereof. The anticoagulant heparin-derived oligosaccharide biphenyl dimer has a structure as represented by general formula I, and a benzene ring can be replaced with substituted phenyl, an aromatic heterocyclic ring or a substituted aromatic heterocyclic ring. The heparin-derived oligosaccharide biphenyl dimer of the present invention has few synthesis steps and a significantly high overall yield, has antithrombin-dependent potent and specific anti-Xa factor activity and no obvious anti-IIa activity, anticoagulant activity being efficiently neutralized by a protamine, and has excellent pharmacokinetics characteristics. Therefore, the present invention is suitable for preparing novel anticoagulant and antithrombotic drugs having cost advantages, and high quality and safety.

The present invention relates to preparation method for the scale up production of a safe bovine heparin composed by a distinctively selected unfractioned bovine heparin polymers with low 6-O-desulfated glucosamine content and a porcine-like anticoagulant activity and protamine neutralization, and methods of its production and application. This safe bovine heparin (SB Heparin) has a comparable structure and function to the porcine heparin, the clinical usage reference, preventing clinical usage impairments as a safe pharmaceutical product, allowing its use as interchangeably drugs.

Establishment and application of a method for detecting heparin by a single-particle level high-sensitivity colorimetric method are as follows: firstly, respectively marking quantum dots with different emission wavelengths by antithrombin III and protamine, and forming a sandwich compound through affinity interaction between the thrombin III and the heparin and electrostatic interaction between the heparin and the protamine; and then judging the formation of a compound through primary spectral stripes of the two quantum dots, and establishing a new heparin detection method on the basis of correlation between the formation quantity of the two quantum dot compounds and the heparin concentration. The linear range of heparin detection is 0.001-0.02 U / mL, and the detection limit is 5.4 * 10 <-6 > U / mL. Meanwhile, the method is used for carrying out heparin labeling recovery detection on the diluted serum, and the recovery rate is 92-106%. The method has the advantages of excellent detection performance, high sensitivity and intuitive and rapid detection result, and provides a new method choice for clinical heparin detection.

Described herein are processes for purifying infectious virus particles and uses of protamine in such processes.

The present invention relates to a cancer-targeting drug delivery system comprising: a protamine-based self-assembling first nanoparticle including a negatively charged substance; and a heparin-based self-assembling second nanoparticle including a positively charged anticancer agent and Fe3+. Specifically, the present invention provides a drug delivery system that forms aggregates at a tumor site by a guidance effect upon administration of the second nanoparticle after administration of the first nanoparticle, and has an anticancer effect through induction of ferroptosis and immunogenic cell death without exhibiting the anticoagulant effect of heparin.

This invention relates to protamine molecules. More specifically, this invention relates to protamine molecules and their use in the delivery of payload molecules.

The invention discloses a protamine mediated fluorescence resonance energy transfer (FRET) sensing system and application thereof. According to the protamine, a tetraphenylethylene-derived anionic molecule (4, 4 '-(((1, 2-stilbene-1, 2-disubunit) bis (4, 1-phenyl)) bis (aza-disubunit)) bis (4-sodium oxobutyrate)) is electrostatically enriched on the surface of the protamine, and a tetraphenylethylene group emits fluorescence after being aggregated and acts as an energy donor; furthermore, cationic dye (4-(4-dimethylaminostyryl)-1-methyl iodide pyridine) is added as an energy receptor, and a fluorescence resonance energy transfer (FRET) system is constructed. Through construction of the FRET system, long-wavelength fluorescence emission can be obtained, high-sensitivity detection of trypsin and screening of enzyme preparations are achieved, and the FRET system is expected to be applied to complex media.

An anticoagulant heparin-chondroitin chimeric saccharide molecule as well as a preparation method and application thereof are disclosed. The anticoagulant heparin-chondroitin chimeric saccharide molecule has a structure as shown in formula I. The heparin-chondroitin chimeric saccharide molecule of the present disclosure has potent activities against an Xa factor and IIa, and the activity of the heparin-chondroitin chimeric saccharide molecule can be effectively neutralized by protamine, with a neutralization rate of greater than or equal to 70%. The risk of causing adverse reactions such as fatal HIT is obviously lower than that of enoxaparin and other low-molecular-weight heparins. The heparin-chondroitin chimeric saccharide molecule disclosed by the present disclosure is suitable for the preparation of a safer potent anticoagulant and antithrombotic new drug.

The invention relates to a hypertension implant rod and a preparation method thereof, and relates to the technical field of hypertension implant rods, the hypertension implant rod comprises a quick release layer, a slow release layer and a long-acting regulation and control layer from outside to inside, the quick release layer comprises, by mass, 60-70% of bacterial cellulose (BC), 15-25% of polydopamine (PDA), 3-8% of ciprofloxacin, 3-8% of protamine and 4-6% of indapamide, the slow release layer comprises, by mass, 20-30% of a long-acting regulation and control layer, and the long-acting regulation and control layer comprises, by mass, 20-30% of a slow release layer and 20-30% of a long-acting regulation and control layer. The sustained release layer is prepared from 55 to 65 percent of polylactic acid-glycolic acid copolymer, 20 to 30 percent of cross-linked gelatin, 8 to 12 percent of lacidipine and 4 to 6 percent of spirolactone, and the long-acting regulation and control layer is prepared from 65 to 75 percent of L-polylactic acid, 20 to 30 percent of beta-glycine crystal, 3 to 5 percent of silk fibroin (SF), 0.5 to 1.0 percent of calcitonin gene related peptide CGRP and 0.1 to 0.3 percent of neuropeptide Y. The hypertension implant rod can be matched with various treatment cycles through gradient degradation, realizes'on-demand treatment ', is high in biocompatibility, is suitable for subcutaneous implantation, and is convenient and safe to operate.

The present invention relates to a lipid nanoparticle-based drug delivery system using recombinant protamine and a method for preparing same. The lipid nanoparticle-based drug delivery system of the present invention can stably deliver a gene to a target cell in vivo by using a recombinant protamine protein having excellent stability when forming a complex with an anionic gene. In addition, the lipid nanoparticle-based drug delivery system can improve the expression level of the gene in the target cell, and thus can be effectively used in related technical fields such as lipid nanoparticle-mediated gene therapy.

The invention discloses a fluorescent probe containing a pyrene group as well as a preparation method and application of the fluorescent probe. The fluorescent probe disclosed by the invention is a ratio type fluorescent molecule, and is combined with protamine through electrostatic interaction to induce emission of excimer. Protamine can be hydrolyzed by adding trypsin, and fluorescence recovery monomer emission is realized, so that trypsin detection is realized. In addition, the probe and gamma-cyclodextrin form a host-guest compound system, and excimer fluorescence emission is shown. Based on the hydrolysis effect of alpha-amylase on cyclodextrin, fluorescence recovers monomer emission, and quantitative detection of alpha-amylase is realized. The invention provides a multifunctional fluorescence detection probe which has good selectivity and sensitivity and can be applied to a serum dilution environment.

The present invention discloses a fluorescent probe containing a pyrene group, and its preparation method and application. The fluorescent probe described in the present invention is a ratiometric fluorescent molecule that binds to protamine through electrostatic interaction to induce the emission of an excimer. The addition of trypsin can hydrolyze the protamine, and the fluorescence can be restored to monomer emission, thereby enabling the detection of trypsin. In addition, the probe forms a host-guest complex system with γ-cyclodextrin, exhibiting the fluorescence emission of the excimer. Based on the hydrolysis of cyclodextrin by α-amylase, the fluorescence can be restored to monomer emission, thereby enabling the quantitative detection of α-amylase. The present invention provides a multifunctional fluorescent detection probe with excellent selectivity and sensitivity, which can be used in a diluted serum environment.

The invention provides a mesenchymal stem cell drug prescription and a preparation process thereof, and belongs to the technical field of biological medicines. The mesenchymal stem cell drug prescription combination provided by the invention comprises a mesenchymal stem cell solution and a self-assembly solution, the mesenchymal stem cell solution is composed of mesenchymal stem cells, human serum albumin, heparin, dextran 40 and a compound electrolyte solution, and the self-assembly solution is composed of protamine, dipotassium glycyrrhizinate, rosmarinic acid and normal saline. The mesenchymal stem cell drug prescription combination provided by the invention can improve the cell viability and stability of the mesenchymal stem cells, highly express CD73, CD90, CD105, HGF and sTNFR1, has a better immune regulation function, and provides a new thought for clinical application of the mesenchymal stem cells.

The present invention relates to protamine molecules. More specifically, the present invention relates to protamine molecules and their use in delivering payload molecules.

The invention discloses a cationic fluorescent probe with long wavelength emission as well as a preparation method and application of the cationic fluorescent probe. The fluorescent probe disclosed by the invention has the characteristic of emitting red fluorescence, the probe is combined with heparin through electrostatic interaction, and the fluorescence is quenched, so that the heparin is detected; furthermore, the protamine is specifically combined with the heparin, probe molecules are released, fluorescence is recovered, and the protamine is detected; the long-wavelength fluorescent probe provided by the invention has good selectivity and sensitivity on heparin and protamine, and can be applied to a serum dilution environment.

The invention relates to the technical field of heparin and protamine analysis, in particular to a method for determining the dosage of heparin and protamine. The method comprises the steps that a first sample set A is obtained, Ai is the ith first sample, and Ai is obtained by adding different doses of preset chemical substances into a blood sample of a target individual; acquiring a whole blood activation blood coagulation time detection result set B; obtaining a target model according to the whole blood activation coagulation time detection result in the step B, the dosage of the corresponding added preset chemical substance and the preset model; and according to the target whole blood activated coagulation time and the target model, obtaining the dosage of a preset chemical substance corresponding to the target whole blood activated coagulation time of the target individual. According to the method, the heparin dosage and the protamine dosage which are suitable for the target individual and correspond to the target whole blood activation coagulation time can be determined, and reference is provided for the heparin dosage and the protamine dosage in an actual application scene.

The invention discloses a tetrapeptide FP4 with a function of relieving diabetic kidney injury as well as a preparation method and application of the tetrapeptide FP4, and belongs to the technical field of biology. The tetrapeptide FP4 is obtained by screening from pacific salmon protamine enzymatic hydrolysate, has an amino acid sequence of FGVP, has the function of relieving the diabetic kidney injury, can significantly reduce the contents of fasting blood-glucose, serum creatinine, urea nitrogen and urine protein of diabetic mice, has better activity and smaller toxic and side effects than a positive drug metformin, and can be used for preparing drugs for treating diabetic kidney injury. The method can be applied to functional food for relieving diabetic kidney injury.